



# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/022,874	12/20/2001	Chika Nakanishi	217408US0CONT	4217
22850 75	7590 04/06/2006		EXAMINER	
OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C. 1940 DUKE STREET ALEXANDRIA, VA 22314			MORRIS, PATRICIA L	
			ART UNIT	PAPER NUMBER
	,		1625	-
			DATE MAIL ED: 04/06/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
Office Action Summary		10/022,874	NAKANISHI ET AL.			
		Examiner	Art Unit			
		Patricia L. Morris	1625			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
WHIC - Exten after: - If NO - Failui Any n	ORTENED STATUTORY PERIOD FOR REPLY HEVER IS LONGER, FROM THE MAILING DA sions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. period for reply is specified above, the maximum statutory period we to reply within the set or extended period for reply will, by statute, eply received by the Office later than three months after the mailing of patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be tim fill apply and will expire SIX (6) MONTHS from to cause the application to become ABANDONED	l. ely filed the mailing date of this communication. O (35 U.S.C. § 133).			
Status						
2a)⊠ 3)□	Responsive to communication(s) filed on <u>06 Fe</u> This action is <b>FINAL</b> . 2b) This Since this application is in condition for allowan closed in accordance with the practice under E	action is non-final. ace except for formal matters, pro				
Dispositi	on of Claims					
<ul> <li>4)  Claim(s) 1.3-7.10-13.20,24,25,27,31 and 32 is/are pending in the application.</li> <li>4a) Of the above claim(s) is/are withdrawn from consideration.</li> <li>5)  Claim(s) is/are allowed.</li> <li>6)  Claim(s) 1.5,6,10,12 and 14 is/are rejected.</li> <li>7)  Claim(s) 3.4.7.11.13.20,24,25,27,31 and 32 is/are objected to.</li> <li>8)  Claim(s) are subject to restriction and/or election requirement.</li> </ul>						
Applicati	on Papers					
10)	The specification is objected to by the Examiner The drawing(s) filed on is/are: a) acce Applicant may not request that any objection to the o Replacement drawing sheet(s) including the correcti The oath or declaration is objected to by the Example.	epted or b) objected to by the Edrawing(s) be held in abeyance. See on is required if the drawing(s) is obj	ected to. See 37 CFR 1.121(d).			
Priority u	nder 35 U.S.C. § 119					
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>						
2) 🔲 Notice	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary ( Paper No(s)/Mail Dat	te			
	nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) No(s)/Mail Date	5) D Notice of Informal Pa 6) Other:	tent Application (PTO-152)			

### **DETAILED ACTION**

Claims 1, 3-7, 10-13, 20, 24, 25, 27, 31 and 32 are under consideration in this application.

## Claim Rejections - 35 USC > 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1, 5, 6, 10, 12 and 14 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

Applicants fail to argue this rejection or amend the claims to put the application in condition for allowance.

Again, the expressions a" lower alkyl group... hetero atom in the ring", "R<sup>6</sup> and R<sup>7</sup> may together form a ring....may have a subsituent" and "substituted" are employed with considerable abandon throughout claims 1, 5, 6, 10, 12 and 14 with no indication given as to what the rings and substituents really are. One, one reading the indication of heterocyclic ring applied by applicants in R<sup>6</sup> and R<sup>7</sup>, has no idea what size ring is being claimed, or where the hetero atoms are in this unknown ring or what the substituents may be. Moreover, the term substituted is employed in claims 1,5, 6, 10, 12 and 14 with no indication of the variables. The term contains is open-ended. What are the substituents on the pyridine and furyl rings? What is meant by the expression cyclic alkyl....which may contain a hetero ring in claim 10?

Art Unit: 1625

One cannot tell from a simple reading of the claim what is being claimed. Also, one must figure which compound treats which disease. One must first conceive of the hetero ring. Further, applicants are claiming that the instant compounds can treat a staggering list of any and all diseases. Then one must, by preparing the compound himself, determine if the hetereo ring or substituents works or not. Where is the specific claiming and distinctly pointing out? How can applicants regard as their invention inexact concepts? The breadth of which they could not have possibly checked out with representative exemplification. The terms are not finite.

Applicants are claiming a compound of the formula. Pure chemistry, a compound. Not a resin of general property ranges, but a pure compound. That compound used for any purpose is taken from the public in a 20-year monopoly to applicants. Then, the public is entitled to know what compound they cannot use. Yet, the claim is not specific to that compound. The public cannot tell what they may not use. How is a claim of the instant breadth defensible in an infringement action?

As applied to pure compounds, In re Cavallito and Gray, 134 USPQ 370, and In re Sus and Schaefer, 134 USPQ 301, are considered to set the proper applicable standard of required definiteness and support.

The written description is considered inadequate here in the specification. Conception of the intended rings and substituents should not be the role of the reader. Applicants should, in return for a 20 year monopoly, be disclosing to the public that which they know as an actual demonstrated fact. The disclosure should not be merely an invitation to experiment. This is a 35 USC 112, first paragraph. If you (the public) find that it works, I claim it, is not a proper basis of patentability. In re Kirk, 153 USPQ 48, at page 53.

## Allowable Subject Matter

Claims 3, 4, 7, 11, 13, 20, 24, 25, 27, 31 and 32 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

#### Conclusion

Claims 1, 5, 6, 10, 12 and 14 are not allowed.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Patricia L. Morris whose telephone number is (571) 272-0688. The examiner can normally be reached on Mondays through Fridays.

The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1625

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Patricia L. Morris Primary Examiner Art Unit 1625

plm April 4, 2006